Which describes you?


Product?

The information contained in this section of the site is for U.S. health care professionals only. Please click "OK" if you are a U.S. health care professional.

The link you selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech is not part of the site. Nor does it control the content. Genentech does not guarantee the information on the page. Your use of third-party websites is at your own risk and is subject to the terms and conditions of use for such sites. 

Do you need to know more about what we offer for each of our products?

Do you want to know more about Pulmozyme Access Solutions? To see what we offer, click here.

 

Questions and Answers About Pulmozyme Access Solutions


If this is your first time working with Pulmozyme® Access Solutions - or even if you've worked with us before - you are bound to have some questions about how our programs work for treatment with Pulmozyme® (dornase alfa) Inhalation Solution. We've assembled a list of questions we are asked most often and provided the answers you might need.

What is Pulmozyme Access Solutions?

We are a service provided by Genentech for Pulmozyme patients and their health care professionals. We help you in resolving specific coverage and reimbursement issues, as well as providing patient assistance for access to Pulmozyme and important information resources.


How do I contact Pulmozyme Access Solutions?

The quickest way to contact us is by calling our toll-free telephone number at (800) 690-3023. Our toll-free fax number is (800) 963-1792. Our mailing address is:

Pulmozyme Access Solutions
 1 DNA Way, Mail Stop #858a
South San Francisco, CA 94080-4990


When does Pulmozyme Access Solutions start helping with my patient's case?

We can start helping to connect your patient to Pulmozyme as soon as we have received the completed required forms.


Should I contact Pulmozyme Access Solutions about general questions about Pulmozyme?

No. You should direct your questions about Pulmozyme to 888-PLMZYME (888-756-9963). Pulmozyme Access Solutions can only answer questions about access and reimbursement.


Does Pulmozyme Access Solutions bill claims?

No. Pulmozyme Access Solutions cannot provide any billing services for your practice.


When should I refer my patient to Pulmozyme Access Solutions for help?

At any point in the process of obtaining Pulmozyme for your patient - whether you've just decided to prescribe it for your patient, if you've submitted a prior authorization (PA) request to the insurer and Pulmozyme wasn't approved or if your patient has been on Pulmozyme but is now having insurance issues.


How do I refer my patient to Pulmozyme Access Solutions?

Please see How to Refer Patients to Pulmozyme Access Solutions for more information. 


Do I need to register my Pulmozyme patients with you before treatment begins?

No. There is no need to preregister a patient with us. However, you do need to enroll a patient for our help with issues of access and reimbursement. Pulmozyme Access Solutions is a voluntary program offered at no charge to you or your patients.


Why does Pulmozyme Access Solutions ask for medical documentation?

We provide access and reimbursement support for a patient based on the patient's clinical situation and the insurer's coverage guidelines. Medical documentation is needed for prior authorization (PA) and/or the appeals process.


Can Pulmozyme Access Solutions assist with co-pay issues?

Yes. We can help with co-pay issues. We can explore alternative coverage options and available resources in the community to help with co-pays. We can refer the patient to an independent non-profit organization offering assistance for people prescribed Pulmozyme. (We do not influence or control the operations of these organizations. Nor can we guarantee they will provide co-pay assistance.) Second, we offer the Pulmozyme Access Solutions Co-pay Card Program for eligible patients who have said they need assistance with co-pays.


Is there assistance for uninsured patients who have been prescribed Pulmozyme?

The Genentech® Access to Care Foundation provides help for qualified patients. These include patients who are uninsured or whose health plans have denied payment for Pulmozyme. They must meet certain financial and medical requirements. 


We need to start the patient on Pulmozyme as soon as possible, but the insurance process might take a while. What can we do?

The Pulmozyme StarteRx Program was designed to help just this kind of patient who is new to Pulmozyme. This program is for eligible patients initiating therapy while insurance coverage is being established. It can also be used when a patient changes health care plans.


Pulmozyme (dornase alfa) Inhalation Solution Important Information

Indication and Usage
Daily administration of Pulmozyme in conjunction with standard therapies is indicated in the management of cystic fibrosis (CF) patients to improve pulmonary function. In patients with an FVC 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. 

Safety and efficacy of daily administration have not been demonstrated in patients for longer than 12 months.

Important Safety Information
Pulmozyme should not be used in patients who are allergic to any of its ingredients. Pulmozyme should be used in conjunction with standard therapies for CF. When starting Pulmozyme therapy, patients may experience change in or loss of voice, discomfort in the throat, chest pain, red watery eyes, rash, dizziness, fever, or runny nose. These side effects are usually mild and short-lived.

For further information, please see the Pulmozyme full Prescribing Information. If you have questions, please discuss them with your CF health care team.

Pulmozyme® is a registered trademark and the Access Solutions logo and the Access Solutions Treatment made possible logo are trademarks of Genentech USA, Inc.

© 2010 Genentech USA, Inc. All rights reserved. This site is intended for U.S. residents only.